Foundation Medicine (FMI) Misses Q3 EPS by 4c, Offers FY15 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Foundation Medicine Announces 2015 Third Quarter Results and Recent Highlights
November 3, 2015 4:00 PM ESTYear-over-Year Third Quarter Revenues Grow 54%; FoundationCORE Expands to Approximately 60,000 Patient Cases; ctDNA Product Launch on Track
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ: FMI) today reported financial and operating results for its third quarter ended September 30, 2015. Highlights for the quarter included:
Third quarter revenue of $25.4 million, 54% year-over-year growth; Third quarter revenue from biopharmaceutical customers of $11.7 million, 75% year-over-year growth;... More